Aurinia Pharmaceuticals Inc

NASDAQ:AUPHUnited States

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.

Contact Information

Headquarters

#140, 14315 - 118 AVENUEVICTORIA, BC, Canada T5L 4S6

Phone

250-744-2487

Fax

604-369-4115

Executives

President, Chief Executive Officer, Director

Peter Greenleaf

Chief Financial Officer

Joe Miller

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

Stephen Robertson

Executive Vice President, Operations and Strategy

Matthew Donley

Chief Commercial Officer

Scott Habig